Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.

Area of Science:

• Biomarkers
• Oncology
• Proteomics

Background:

• Ovarian cancer diagnosis is often delayed, leading to poor survival rates.
• Effective screening biomarkers are crucial for early detection and improved patient outcomes.
• Microarray technology was employed to identify overexpressed secretory proteins as potential biomarkers.

Purpose of the Study:

• To investigate prostasin, a serine protease, as a potential serum biomarker for ovarian cancer.
• To evaluate prostasin gene and protein expression in ovarian cancer tissues and serum.
• To assess the diagnostic performance of prostasin, alone and in combination with CA 125.

Main Methods:

• Gene expression analysis using microarray and real-time quantitative PCR.
• Immunostaining of prostasin in ovarian tissues.
• Serum prostasin measurement via enzyme-linked immunosorbent assay (ELISA).
• Comparison with CA 125 levels in case patients and control subjects.

Main Results:

• Prostasin showed stronger immunostaining in cancerous ovarian cells and stroma compared to normal tissue.
• Mean serum prostasin levels were significantly higher in ovarian cancer patients (13.7 microg/mL) than in controls (7.5 microg/mL) (P<.001).
• Postoperative serum prostasin levels decreased significantly in most patients (P =.004).
• The combination of prostasin and CA 125 achieved 92% sensitivity and 94% specificity for ovarian cancer detection.

Conclusions:

• Prostasin is overexpressed in epithelial ovarian cancer.
• Prostasin warrants further investigation as a standalone or combination biomarker for ovarian cancer screening.
• The combination of prostasin and CA 125 demonstrates high potential for improving ovarian cancer diagnostics.